Email Updates

AGORACOM News Flash

AGORACOM WIRE .... TUESDAY FEBRUARY 14TH

UPDATE 1:30PM

Graphite is the Emerging Investment Story of 2012

Graphite Investment Conference Vancouver

Find out more today!

Breaking News ....

Strike Graphite Corp. (TSXV:SRK) Acquires Wagon Graphite Project in Quebec in Vicinity of Timcal's Lac des Iles Graphite Mine *CLIENT Read More | Profile

Strike Graphite goes "Beyond the Press Release"

McLaren Resources (CNSX:MCL) Drills 7.0 Grams Gold Over 7.4 Metres at the TimGinn Property Located Adjacent to the Hollinger Mine *CLIENT* Read More | Watch Beyond the Press Release

AGORACOM Launches GraphiteStocksBlog.com

We're proud to announce the launch of GraphiteStocksBlog.com a website dedicated to the needs of investors and companies in the fast growing Graphite industry.

INAUGURAL GRAPHITE SPONSORS

Message: Biocurex has no competition

Reply New Message

Back To Forum Go to List View

Half Full Glass

Rank: [?]

Vice President

Points: [?]

1181

Rating: [?]

Votes: 15 Score: 3.6

Currently 3.6/5 Stars.

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

Biocurex has no competition

posted on Nov 05, 08 01:49PM

Gold keeps refering to DR-70 and has attempted to compare it to Recaf. No WAY !!! No WAY !!! No WAY !!!

China should be very excited about the arival of Recaf.

BioCurex is very pleased to report the results obtained using the RECAF ELISA test on 77 bladder, kidney, stomach, and other types of cancers in comparison to 93 normal donor samples. It also compared the results with the chemiluminescence format. The results evidence a sensitivity of 90% with 95% specificity. Sensitivity is the ability of a test to detect existing cancers (if all patients who have a cancer test positive = 100% sensitivity).

Specificity represents how well the test avoids false positives (no false positives = 100% specificity). The regression coefficient (r) between the RECAF-ELISA and the RECAF-chemiluminescence test was 0.92 (maximum = 1) and the diagnostic correspondence between both tests was 97.8%. The work was done in collaboration with the Blokhin Cancer Research Centre, Moscow, Russia, and BioCurex expects to present the results at an International cancer congress later this year.
http://www.medicalnewstoday.com/arti...

Dr-70 ELISA has a sensitivity of 67 and a Specificity of 68. I would say that this is equivelant to existing tests. Very poor.

http://www.fda.gov/cdrh/reviews/K072...

Reply New Message

Back To Forum Go to List View